Preeclampsia and Diabetes
- 1k Downloads
Preeclampsia is diagnosed in women presenting with new onset hypertension accompanied by proteinuria or other signs of severe organ dysfunction in the second half of pregnancy. Preeclampsia risk is increased 2- to 4-fold among women with type 1 or type 2 diabetes. The limited number of pregnant women with preexisting diabetes and the difficulties associated with diagnosing preeclampsia in women with proteinuria prior to pregnancy are significant barriers to research in this high-risk population. Gestational diabetes mellitus (GDM) also increases preeclampsia risk, although it is unclear whether these two conditions share a common pathophysiological pathway. Nondiabetic women who have had preeclampsia are more likely to develop type 2 diabetes later in life. Among women with type 1 diabetes, a history of preeclampsia is associated with an increased risk of retinopathy and nephropathy. More research examining the pathophysiology, treatment, and the long-term health implications of preeclampsia among women with preexisting and gestational diabetes is needed.
KeywordsPreeclampsia Type 1 diabetes Type 2 diabetes Gestational diabetes
Tracey L. Weissgerber and Lanay M. Mudd were supported by Building Interdisciplinary Careers in Women’s Health awards from the Office of Women’s Health Research (TLW: K12HD065987; LMM: K12HD065879-03).
Compliance with Ethics Guidelines
Conflict of Interest
Tracey L. Weissgerber and Lanay M. Mudd declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.World Health Organization. World Health Report: make every mother, and child count. Geneva: WHO 2005.Google Scholar
- 5.••Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstetrics and gynecology. 2013;122(5):1122-31. doi: 10.1097/01.AOG.0000437382.03963.88. This paper outlines new ACOG criteria for the diagnosis of preeclampsia.
- 6.•Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57(12):1404–23. doi: 10.1016/j.jacc.2011.02.005. This American Heart Association guideline identifies preeclampsia as a major risk factor for future cardiovascular disease in women.CrossRefPubMedCentralPubMedGoogle Scholar
- 7.•Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(5):1545–88. doi: 10.1161/01.str.0000442009.06663.48. This American Heart Association guideline identifies preeclampsia as a risk factor for stroke years after pregnancy.CrossRefPubMedGoogle Scholar
- 9.Jauniaux E, Hempstock J, Greenwold N, Burton GJ. Trophoblastic oxidative stress in relation to temporal and regional differences in maternal placental blood flow in normal and abnormal early pregnancies. Am J Pathol. 2003;162(1):115–25. doi: 10.1016/S0002-9440(10)63803-5.CrossRefPubMedCentralPubMedGoogle Scholar
- 11.Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Investig. 2003;111(5):649–58. doi: 10.1172/JCI17189.CrossRefPubMedCentralPubMedGoogle Scholar
- 20.Groen B, Links TP, van den Berg PP, Hellinga M, Moerman S, Visser GH, et al. Similar adverse pregnancy outcome in native and nonnative Dutch women with pregestational type 2 diabetes: a multicentre retrospective study. ISRN Obstet Gynecol. 2013;2013:361435. doi: 10.1155/2013/361435.CrossRefPubMedCentralPubMedGoogle Scholar
- 23.••Holmes VA, Young IS, Patterson CC, Pearson DW, Walker JD, Maresh MJ, et al. Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial. Diabetes Care. 2011;34(8):1683–8. doi: 10.2337/dc11-0244. This paper from a large randomized controlled trial of vitamin C and E to prevent preeclampsia in women with type 1 diabetes shows that poor glycemic control is an independent risk factor for preeclampsia.CrossRefPubMedCentralPubMedGoogle Scholar
- 26.••Myatt L, Redman CW, Staff AC, Hansson S, Wilson ML, Laivuori H, et al. Strategy for standardization of preeclampsia research study design. Hypertension. 2014;63(6):1293–301. doi: 10.1161/HYPERTENSIONAHA.113.02664. This guideline describes methods for standardizing and optimizing study design and data collection in preeclampsia studies.CrossRefPubMedGoogle Scholar
- 27.Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998;338(11):701–5. doi: 10.1056/NEJM199803123381101.CrossRefPubMedGoogle Scholar
- 28.McCance DR, Holmes VA, Maresh MJ, Patterson CC, Walker JD, Pearson DW, et al. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial. Lancet. 2010;376(9737):259–66. doi: 10.1016/S0140-6736(10)60630-7.CrossRefPubMedCentralPubMedGoogle Scholar
- 31.••Holmes VA, Young IS, Patterson CC, Maresh MJ, Pearson DW, Walker JD, et al. The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes. Diabetes Care. 2013;36(11):3671–7. doi: 10.2337/dc13-0944. This secondary analysis of a randomized controlled trial is the largest study examining the potential value of sFlt-1, sEng and PGF to predict preeclampsia in women with type 1 diabetes.CrossRefPubMedCentralPubMedGoogle Scholar
- 33.Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, et al. Soluble fms-like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One. 2010;5(10):e13263. doi: 10.1371/journal.pone.0013263.CrossRefPubMedCentralPubMedGoogle Scholar
- 35.•Zamudio S, Kovalenko O, Echalar L, Torricos T, Al-Khan A, Alvarez M, et al. Evidence for extraplacental sources of circulating angiogenic growth effectors in human pregnancy. Placenta. 2013;34(12):1170–6. doi: 10.1016/j.placenta.2013.09.016. This paper identifies methodological factors that influence measured concentrations of pro-angiogenic and anti-angiogenic factors. These factors must be accurately controlled to ensure the accuracy of study conclusions.CrossRefPubMedGoogle Scholar
- 40.Blum S, Milman U, Shapira C, Miller-Lotan R, Bennett L, Kostenko M, et al. Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler Thromb Vasc Biol. 2008;28(3):e18–20. doi: 10.1161/ATVBAHA.107.159905.CrossRefPubMedGoogle Scholar
- 44.Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol. 2008;28(2):341–7. doi: 10.1161/ATVBAHA.107.153965.CrossRefPubMedGoogle Scholar
- 50.Villar J, Purwar M, Merialdi M, Zavaleta N, Thi Nhu Ngoc N, Anthony J, et al. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG. 2009;116(6):780–8. doi: 10.1111/j.1471-0528.2009.02158.x.CrossRefPubMedGoogle Scholar
- 56.•Weissgerber TL, Gandley RE, Roberts JM, Patterson CC, Holmes VA, Young IS, et al. Haptoglobin phenotype and preeclampsia incidence in women with type 1 diabetes supplemented with vitamins C and E. Br J Obstet Gynecol. 2013;120(10):1192–9. This secondary analysis of a randomized, controlled trial shows that Hp phenotype does not influence preeclampsia risk or the effectiveness of vitamin C and E supplementation in preventing preeclampsia in women with type 1 diabetes.CrossRefGoogle Scholar
- 57.Weissgerber TL, Gandley RE, McGee PL, Spong CY, Myatt L, Leveno KJ, et al. Haptoglobin phenotype, preeclampsia risk and the efficacy of vitamin C and E supplementation to prevent preeclampsia in a racially diverse population. PLoS One. 2013;8(4):e60479. doi: 10.1371/journal.pone.0060479.CrossRefPubMedCentralPubMedGoogle Scholar
- 60.Wendland EM, Torloni MR, Falavigna M, Trujillo J, Dode MA, Campos MA, et al. Gestational diabetes and pregnancy outcomes—a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria. BMC Pregnancy Childbirth. 2012;12:23. doi: 10.1186/1471-2393-12-23.CrossRefPubMedCentralPubMedGoogle Scholar
- 65.••Schneider S, Freerksen N, Rohrig S, Hoeft B, Maul H. Gestational diabetes and preeclampsia—similar risk factor profiles? Early Hum Dev. 2012;88(3):179–84. doi: 10.1016/j.earlhumdev.2011.08.004. By using a perinatal health registry, this study was able to accurately describe prevalence rates for gestational diabetes, preeclampsia, and the co-occurrence of these two conditions within Germany. It also describes risk factors common to both conditions.CrossRefPubMedGoogle Scholar
- 69.•Barquiel B, Herranz L, Grande C, Castro-Dufourny I, Llaro M, Parra P, et al. Body weight, weight gain and hyperglycaemia are associated with hypertensive disorders of pregnancy in women with gestational diabetes. Diabetes Metab. 2014;40(3):204–10. doi: 10.1016/j.diabet.2013.12.011. This study showed that while pre-pregnancy weight status was the strongest risk factor for preeclampsia, gestational weight gain and glycemic control were also independent risk factors.CrossRefPubMedGoogle Scholar
- 71.Conti E, Zezza L, Ralli E, Caserta D, Musumeci MB, Moscarini M, et al. Growth factors in preeclampsia: a vascular disease model. A failed vasodilation and angiogenic challenge from pregnancy onwards? Cytokine Growth Factor Rev. 2013;24(5):411–25. doi: 10.1016/j.cytogfr.2013.05.008.CrossRefPubMedGoogle Scholar
- 72.de Resende Guimaraes MF, Brandao AH, de Lima Rezende CA, Cabral AC, Brum AP, Leite HV, et al. Assessment of endothelial function in pregnant women with preeclampsia and gestational diabetes mellitus by flow-mediated dilation of brachial artery. Arch Gynecol Obstet. 2014;290(3):441–7. doi: 10.1007/s00404-014-3220-x.CrossRefGoogle Scholar
- 74.Karacay O, Sepici-Dincel A, Karcaaltincaba D, Sahin D, Yalvac S, Akyol M, et al. A quantitative evaluation of total antioxidant status and oxidative stress markers in preeclampsia and gestational diabetic patients in 24–36 weeks of gestation. Diabetes Res Clin Pract. 2010;89(3):231–8. doi: 10.1016/j.diabres.2010.04.015.CrossRefPubMedGoogle Scholar
- 77.•Wen SW, Xie RH, Tan H, Walker MC, Smith GN, Retnakaran R. Preeclampsia and gestational diabetes mellitus: pre-conception origins? Med Hypotheses. 2012;79(1):120–5. doi: 10.1016/j.mehy.2012.04.019. This paper provides a review of hypothesized etiological pathways for preeclampsia and gestational diabetes and argues that both of these conditions have their origins in pre-pregnancy maternal health.CrossRefPubMedGoogle Scholar
- 82.••Poolsup N, Suksomboon N, Amin M. Effect of treatment of gestational diabetes mellitus: a systematic review and meta-analysis. PLoS One. 2014;9(3):e92485. doi: 10.1371/journal.pone.0092485. This meta-analysis examines the effects of treating gestational diabetes on a range of pregnancy outcomes, including risk of diabetes. Results showed no effect on preeclampsia risk, although only three randomized trials have examined preeclampsia as a secondary outcome and the confidence intervals are extremely wide, indicating low power to detect a relationship.CrossRefPubMedCentralPubMedGoogle Scholar
- 84.•Engeland A, Bjorge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, et al. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway. Eur J Epidemiol. 2011;26(2):157–63. doi: 10.1007/s10654-010-9527-4. Previous studies had very low power to examine future disease risk among women who developed both gestational diabetes and preeclampsia. Using a national birth registry, this study was able to more precisely estimate the risk of diabetes 5 years postpartum in relation to preeclampsia alone, gestational diabetes alone and both conditions combined.CrossRefPubMedCentralPubMedGoogle Scholar
- 86.Libby G, Murphy DJ, McEwan NF, Greene SA, Forsyth JS, Chien PW, et al. Pre-eclampsia and the later development of type 2 diabetes in mothers and their children: an intergenerational study from the Walker cohort. Diabetologia. 2007;50(3):523–30. doi: 10.1007/s00125-006-0558-z.CrossRefPubMedGoogle Scholar
- 90.Lovestam-Adrian M, Agardh CD, Aberg A, Agardh E. Pre-eclampsia is a potent risk factor for deterioration of retinopathy during pregnancy in type 1 diabetic patients. Diabetic Med. 1997;14(12):1059–65. doi: 10.1002/(SICI)1096-9136(199712)14:12<1059::AID-DIA505>3.0.CO;2-8.CrossRefPubMedGoogle Scholar